BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingGlobeNewsWire • Wednesday
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialGlobeNewsWire • Monday
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's DementiaGlobeNewsWire • 04/10/24
BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineGlobeNewsWire • 03/15/24
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023GlobeNewsWire • 03/12/24
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024GlobeNewsWire • 03/01/24
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)GlobeNewsWire • 02/12/24
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®GlobeNewsWire • 02/06/24
BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of DexmedetomidineGlobeNewsWire • 02/05/24
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage ProgramsGlobeNewsWire • 12/11/23
BioXcel Therapeutics stock plummets as 3Q earnings fall short of expectationsProactive Investors • 11/14/23
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/14/23
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma PhenotypeGlobeNewsWire • 11/08/23